cas 95-14-7|| where to buy 1H-Benzotriazole

Produktname:1H-Benzotriazole

IUPAC Name:1H-1,2,3-benzotriazole

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 95-14-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:95-14-7; Molekulare Formel:C6H5N3; Schmelzpunkt:-; SMILES-Code:N1=NC=2C=CC=CC2N1; Dichte:

: Katalognummer:CM158391; Molekulargewicht:119.13; Siedepunkt:; Mdl-Nr.:MFCD00005699; Lagerung:Store at room temperature.

: Benzotriazoles; Benzotriazole is a bicyclic nitrogen heterocycle formed by the fusion of the benzene ring with the 4,5-positions or the “d” site of 1H-1,2,3-triazole. The benzotriazoles are known as important intermediates in the preparation of organic products such as β-amido ketones, aldehydes, β-ketoesters, ionic liquid, and as reagents for acylation and thioacylation reactions. 1H-Benzotriazoles are also known to exhibit broad spectrum of pharmacological activities. There are numerous benzotriazole-based clinically used drugs in the market for the treatment of various diseases.

: Obicetrapib; The elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), and heterozygous familial hypercholesterolemia (HeFH). Cholesteryl ester transfer protein (CETP) transports cholesterol from good high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C). NewAmsterdam’s Obicetrapib is a novel, selective CETP inhibitor to address the limitations of current treatments.
Obicetrapib is under investigation in phase III clinical trials as a monotherapy product, and in phase II studies as a fixed dose combination with Ezetimibe.